A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Hydroxyurea (DROXIA)

Antimetabolite class · 4 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval1998-10-19
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$21.1M in CY2024 Part D spend805K claims · 216K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.199/unit
13 NDCs benchmarked, lowest of all strengths.
Average NADAC
$5.91
Across all dosage forms in distribution.
Highest NADAC
$62.03
Wide spread — brand-strength NDCs still in market.
Plans with PA
38 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Hydroxyurea used for?

Hydroxyurea is a Antimetabolite medication tracked in Medicare Part D.

Is there a generic for Hydroxyurea?

Yes. 4 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Hydroxyurea?

Across 329 Part D plans, Hydroxyurea averages $5.91/unit (NADAC). Lowest available: $0.199/unit. Highest in distribution: $62.03/unit.

Is Hydroxyurea on the FDA shortage list?

No. Hydroxyurea is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Antimetabolite1 alternative in D1
01
Floxuridine
Antimetabolite
Lowest NADAC
2Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (13 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.